Compare PDD Holdings Inc. American Depositary Shares (PDD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PDD Holdings Inc. American Depositary Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $80 (market cap $116.66B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 15.5× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, PDD Holdings Inc. American Depositary Shares nearer its low. Which is the better fit depends on your goals.
| PDD | SYRE | |
|---|---|---|
Market Cap | $116.66B | $7.52B |
Volume | 9,095,378 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $108.92 |
52-Week Low | $73.30 | $22.18 |
Enterprise Value | $49.19B | $6.52B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDD Holdings trades at $81.96, up 1.29% with a bullish technical signal despite recent earnings volatility. The stock shows strong fundamentals with a P/E of 8.81 and robust profitability margins (net income margin 20.43%). Recent news highlights investor attention and the company's major investment cycle while facing regulatory and competitive pressures.
The outlook remains cautiously optimistic with a $99.13 consensus price target, though risks include trade policy impacts and execution challenges from PDD's shift to an asset-heavy model. Earnings misses in recent quarters and moderating revenue growth warrant close monitoring for sustained investor confidence.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PDD Holdings Inc. American Depositary Shares
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
